Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
received only the liquid (adjuvant) of the Shingrix vaccine; received only the liquid (adjuvant) of the Shingrix vaccine; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a 52-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. In JUL-2024, the patient received the 1st dose of Shingrix. In JUL-2024, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: received only the liquid (adjuvant) of the Shingrix vaccine) and inappropriate dose of vaccine administered (Verbatim: received only the liquid (adjuvant) of the Shingrix vaccine). Additional Information: GSK Receipt Date: 22-JAN-2026 The physician practice manager had called to report that one of two patients had received only the liquid (adjuvant) portion of the Shingrix vaccine and stated that they were not sure which patient had received only the liquid portion, noting that both patients had been vaccinated on 15-DEC-2025, and asking how long they had to administer a full dose. The patient number one received a first dose back on JUL-2024. This case is 1 of 3 cases reported by same reporter. The batch number was not provided upon follow up with the reporter.; Sender's Comments: US-GSK-US2026010943:SAME REPORTER US-GSK-US2026010943:SAME REPORTER